KR930007386B1 - γ-사이클로덱스트린 유도체의 제조방법 - Google Patents

γ-사이클로덱스트린 유도체의 제조방법 Download PDF

Info

Publication number
KR930007386B1
KR930007386B1 KR1019860000831A KR860000831A KR930007386B1 KR 930007386 B1 KR930007386 B1 KR 930007386B1 KR 1019860000831 A KR1019860000831 A KR 1019860000831A KR 860000831 A KR860000831 A KR 860000831A KR 930007386 B1 KR930007386 B1 KR 930007386B1
Authority
KR
South Korea
Prior art keywords
alkyl
active ingredient
derivative
cyclodextrin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019860000831A
Other languages
English (en)
Korean (ko)
Other versions
KR860009032A (ko
Inventor
빌리 베르너 뮐러 베른트
Original Assignee
쟈안센 파아마슈우티카 엔. 부이.
폴 아드리안 쟈안센
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟈안센 파아마슈우티카 엔. 부이., 폴 아드리안 쟈안센 filed Critical 쟈안센 파아마슈우티카 엔. 부이.
Publication of KR860009032A publication Critical patent/KR860009032A/ko
Application granted granted Critical
Publication of KR930007386B1 publication Critical patent/KR930007386B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019860000831A 1985-03-15 1986-02-06 γ-사이클로덱스트린 유도체의 제조방법 Expired - Lifetime KR930007386B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8506792 1985-03-15
GB858506792A GB8506792D0 (en) 1985-03-15 1985-03-15 Derivatives of y-cyclodextrin

Publications (2)

Publication Number Publication Date
KR860009032A KR860009032A (ko) 1986-12-19
KR930007386B1 true KR930007386B1 (ko) 1993-08-09

Family

ID=10576063

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860000831A Expired - Lifetime KR930007386B1 (ko) 1985-03-15 1986-02-06 γ-사이클로덱스트린 유도체의 제조방법

Country Status (22)

Country Link
US (1) US4764604A (https=)
EP (2) EP0197571B1 (https=)
JP (1) JP2562809B2 (https=)
KR (1) KR930007386B1 (https=)
AT (2) ATE124055T1 (https=)
AU (1) AU583599B2 (https=)
CA (1) CA1300130C (https=)
CY (1) CY1918A (https=)
DE (2) DE3650655T2 (https=)
DK (1) DK176156B1 (https=)
ES (1) ES8705899A1 (https=)
FI (1) FI84076C (https=)
GB (1) GB8506792D0 (https=)
GR (1) GR860685B (https=)
HK (1) HK131896A (https=)
HU (2) HU198092B (https=)
IE (1) IE66673B1 (https=)
NO (1) NO167578C (https=)
NZ (1) NZ215350A (https=)
PT (1) PT82186B (https=)
SG (1) SG48788A1 (https=)
ZA (1) ZA861930B (https=)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6333341A (ja) * 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd 配糖体の処理方法
JPS63117003A (ja) * 1986-10-31 1988-05-21 Agency Of Ind Science & Technol シクロデキストリン誘導体
DE3744742C2 (https=) * 1986-10-31 1993-03-11 Director-General Of Agency Of Industrial Science And Technology, Tokio/Tokyo, Jp
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
IT1203968B (it) * 1987-04-24 1989-02-23 Bononi Ricerca Complessi di b-ciclodestrina ad attivita' antimicotica
NZ224497A (en) * 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5760015A (en) * 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
US5637575A (en) * 1988-01-19 1997-06-10 The Trustees Of The University Of Pennsylvania Methods of inhibiting restenosis
DE68910113T2 (de) * 1988-01-19 1994-03-17 Childrens Hospital Corp Wachstuminhibierendes mittel und dessen verwendung.
US5183809A (en) * 1990-02-15 1993-02-02 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5236944A (en) * 1988-03-28 1993-08-17 Janssen Pharmaceutica N.V. Compounds, compositions and anti-neoplastic methods
WO1989010739A1 (en) * 1988-05-11 1989-11-16 Board Of Regents, The University Of Texas System Hydroxyalkyl cyclodextrin-antifungal polyene antibiotics complexes
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
AU616571B2 (en) * 1988-10-28 1991-10-31 Shiseido Company Ltd. Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
HK1009335A1 (en) * 1989-04-03 1999-05-28 Janssen Pharmaceutica N.V. Regioselective substitutions in cyclodextrins
US5096893A (en) * 1989-04-03 1992-03-17 The United States Of America As Represented By The Department Of Health And Human Services Regioselective substitutions in cyclodextrins
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
AU5594190A (en) * 1989-06-02 1990-12-06 Ciba-Geigy Ag Intravenous solutions with a rapid onset of action
SE8902235D0 (sv) * 1989-06-20 1989-06-20 Haessle Ab Novel cyclodextrin inclusion complexes
US5154738A (en) * 1989-09-12 1992-10-13 Advanced Separation Technologies, Inc. Chiral separation media
US5064944A (en) * 1989-09-12 1991-11-12 Advanced Separation Technologies Inc. Chiral separation media
WO1991004026A1 (en) * 1989-09-14 1991-04-04 Australian Commercial Research & Development Limited Drug delivery compositions
EP0435826A1 (de) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenöse Lösungen für Status Epilepticus
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
HU212730B (en) * 1990-03-28 1996-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
DE69127256T2 (de) * 1990-05-21 1998-02-12 Toppan Printing Co Ltd Cyclodextrinderivat
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
JP2711759B2 (ja) * 1990-10-24 1998-02-10 エスエス製薬 株式会社 止瀉剤組成物
CA2061891A1 (en) * 1991-03-08 1992-09-09 Robert F. Van Ginckel Flunarizine containing anti-neoplastic compositions
US5446030A (en) * 1991-09-19 1995-08-29 Weisz; Paul B. Prevention of hemolysis
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
JPH05262764A (ja) * 1992-01-24 1993-10-12 Morishita Roussel Kk １−アリール−２−（１ｈ−１，２，４−トリアゾー ル−１−イル）エタノール誘導体
US5300280A (en) * 1992-02-14 1994-04-05 Mallinckrodt Medical, Inc. Stabilized radiopharmaceutical kits
CA2117651C (en) * 1992-03-18 2006-01-03 Jan Heeres Itraconazole and saperconazole stereoisomers
FR2693728B1 (fr) * 1992-07-17 1994-09-23 Orsan Procédé de fabrication de cyclodextrines partiellement méthylées et composés obtenus.
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
EP0687174B1 (en) * 1993-03-05 2001-06-13 Hexal Ag Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation
US6346518B1 (en) 1993-03-10 2002-02-12 Janssen Pharmaceutica N.V. Itraconazole and saperconazole stereoisomers
EP0697874A1 (en) * 1993-03-31 1996-02-28 The Trustees Of The University Of Pennsylvania Methods of affecting the growth of living tissue in mammals and compounds and compositions therefor
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
DE4333598A1 (de) * 1993-10-01 1995-04-06 Consortium Elektrochem Ind Verfahren zur Herstellung von alkylierten Cyclodextrin-Derivaten, nach dem Verfahren herstellbare methylierte Cyclodextrin-Derivate und die Verwendung der Produkte
ZA949715B (en) * 1993-12-14 1996-06-06 Lilly Co Eli Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins and pharmaceutical formulations and methods thereof
DE4414138A1 (de) * 1994-04-22 1995-10-26 Consortium Elektrochem Ind Acylierte gamma-Cyclodextrine
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
DE4428654A1 (de) * 1994-08-12 1996-02-15 Consortium Elektrochem Ind Wasserlösliche Cyclodextrinderivate mit lipophilen Substituenten und Verfahren zu ihrer Herstellung
US5679573A (en) * 1995-07-27 1997-10-21 Abbott Laboratories Stabilized aqueous steroid immunoassay standards with cyclodextrins
US5935941A (en) * 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US5681828A (en) * 1995-12-19 1997-10-28 Pitha; Josef Selective alkylations of cyclodextrins leading to derivatives which have a rigidly extended cavity
US5891909A (en) * 1996-03-29 1999-04-06 3-Dimensional Pharmaceuticals, Inc. Amidinohydrazones as protease inhibitors
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
EP0838225A3 (en) * 1996-10-25 1999-03-24 Hiji, Yasutake Aqueous local anesthetic solution
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
JP3608800B2 (ja) * 1997-03-26 2005-01-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗真菌剤およびポリマーでコートされたコアを有するペレット剤
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
CA2317106C (en) 1997-12-31 2004-11-23 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6344486B1 (en) 1998-04-03 2002-02-05 3-Dimensional Pharmaceuticals, Inc. Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors
WO1999055355A1 (en) 1998-04-24 1999-11-04 3-Dimensional Pharmaceuticals, Inc. Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
US7091192B1 (en) * 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
AR020650A1 (es) * 1998-08-10 2002-05-22 Poly Med Inc Polimeros fosforilados y conjugados de los mismos
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
ES2251985T3 (es) 1999-03-24 2006-05-16 R.P. Scherer Technologies, Inc. Particula granulada para mejorar la solubilidad acuosa de farmacos, y su procedimiento de preparacion.
WO2000073302A1 (en) 1999-05-27 2000-12-07 3-Dimensional Pharmaceuticals, Inc. Oxazaheterocycles as protease inhibitors
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
DE19930553A1 (de) * 1999-07-02 2001-01-11 Wacker Chemie Gmbh Verfahren zur Herstellung von alkylierten Cyclodextrin-Derivaten
DE60005351D1 (de) 1999-07-09 2003-10-23 Dimensional Pharm Inc Heteroaryl protease inhibitoren und diagnostische bilderzeugungsmittel
US8614291B2 (en) * 1999-08-10 2013-12-24 Poly-Med, Inc. Phosphorylated polymers and conjugates thereof
DE60006407T2 (de) * 1999-09-13 2004-09-09 3-Dimensional Pharmaceuticals, Inc. Azazykloalkanone serin-protease-hemmer
US6784165B1 (en) * 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
FR2808691B1 (fr) 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
AU2001259725A1 (en) 2000-05-15 2001-11-26 The Procter And Gamble Company Compositions comprising cyclodextrin derivatives
CA2415932A1 (en) * 2000-07-17 2002-01-24 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine pyrazinones as protease inhibitors
CA2417914A1 (en) 2000-08-04 2002-02-14 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine protease inhibitors
IL155959A0 (en) 2000-11-28 2003-12-23 Fmc Corp Edible pga (propylene glycol alginate) coating composition
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004000284A1 (en) * 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
HRP20041220A2 (hr) * 2002-05-28 2006-04-30 3-Dimensional Pharmaceuticals Novi tiofen amidini, njihovi pripravci i postupci liječenja komplementom posredovanih bolesti i stanja
US6828311B2 (en) 2002-05-29 2004-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Formulation for the parenteral application of a sodium channel blocker
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BRPI0314042B8 (pt) 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20040248850A1 (en) * 2003-02-11 2004-12-09 Kemia, Inc. Compounds for the treatment of HIV infection
HRP20050924A2 (en) * 2003-03-28 2006-08-31 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
ES2409884T3 (es) * 2003-03-28 2013-06-28 Ares Trading S.A. Formulaciones orales de cladribina
JP2006522809A (ja) 2003-04-10 2006-10-05 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド 置換フェニルアセトアミおよびプロテアーゼインヒビターとしてのその使用
MXPA05011428A (es) * 2003-04-24 2006-05-31 Aderis Pharmaceuticals Inc Metodo de tratamiento de fibrilacion atrial o trepidacion auricular.
UA81305C2 (en) 2003-07-02 2007-12-25 Ares Trading Sa Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture
JP2007500729A (ja) * 2003-07-31 2007-01-18 アイバックス コーポレイション 雄性及び雌性の性機能障害の治療方法
US7504401B2 (en) * 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
DE10344967B4 (de) * 2003-09-07 2011-07-28 Henkel AG & Co. KGaA, 40589 Alkoxylgruppen-haltige Cyclodextrin-Derivate; Verfahren zu deren Herstellung und deren Verwendung
US20050118262A1 (en) * 2003-09-17 2005-06-02 Jack Aurora Controlled release formulation
MXPA06002766A (es) 2003-09-22 2006-12-14 Baxter Int Esterilizacion a alta presion para esterilizar terminalmente preparaciones farmaceuticas y productos medicos.
CN1294912C (zh) * 2004-03-01 2007-01-17 上海医药工业研究院 伊曲康唑盐酸盐组合物及其冻干粉针
WO2007109459A2 (en) * 2006-03-21 2007-09-27 Janssen Pharmaceutica, Nv Pyridines and pyridine n-oxides as modulators of thrombin
KR20090010953A (ko) 2006-03-28 2009-01-30 자블린 파머슈티칼스 인코포레이티드 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008105808A2 (en) 2006-07-28 2008-09-04 Onconova Therapeutics, Inc. FORMULATIONS OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2155705A4 (en) 2007-06-08 2012-02-15 Univ Georgia State Res Found COMPOSITIONS FOR REGULATING OR MODULATING QUORUM DETECTION IN BACTERIA, METHODS OF USING THE SAME, AND METHODS OF REGULATING AND MODULATING QUORUM DETECTION IN BACTERIUM
JP5048398B2 (ja) * 2007-06-13 2012-10-17 大蔵製薬株式会社 抗真菌剤の医薬組成物
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
EP2194429A1 (en) * 2008-12-02 2010-06-09 Eastman Kodak Company Gumming compositions with nano-particles for improving scratch sensitivity in image and non-image areas of lithographic printing plates
AU2010321533A1 (en) * 2009-11-23 2012-05-31 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
MY166036A (en) 2011-07-20 2018-05-21 Hospira Inc Methods of treating pain
CN102499909B (zh) * 2011-12-27 2013-08-07 哈尔滨三联药业有限公司 伊曲康唑分散片及其制备方法
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
JPS58173102A (ja) * 1982-04-06 1983-10-12 Teijin Ltd エ−テル化サイクロデキストリンの単離精製法
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives

Also Published As

Publication number Publication date
DE3650336D1 (de) 1995-07-27
DK121486A (da) 1986-09-16
GR860685B (en) 1986-07-11
US4764604A (en) 1988-08-16
ZA861930B (en) 1987-10-28
SG48788A1 (en) 1998-05-18
DE3650336T2 (de) 1995-11-02
EP0636634A1 (en) 1995-02-01
EP0636634B1 (en) 1997-11-05
AU583599B2 (en) 1989-05-04
NO860971L (no) 1986-09-16
CY1918A (en) 1997-03-07
HU198092B (en) 1989-07-28
HUT42514A (en) 1987-07-28
JPS61275301A (ja) 1986-12-05
NO167578C (no) 1991-11-20
FI84076C (fi) 1991-10-10
NO167578B (no) 1991-08-12
FI861064L (fi) 1986-09-16
FI861064A0 (fi) 1986-03-14
HK131896A (en) 1996-07-26
ES552984A0 (es) 1987-05-16
EP0197571A3 (en) 1987-09-30
EP0197571A2 (en) 1986-10-15
IE860685L (en) 1986-09-15
DK176156B1 (da) 2006-10-23
US4764604B1 (https=) 1990-06-12
ATE124055T1 (de) 1995-07-15
KR860009032A (ko) 1986-12-19
ES8705899A1 (es) 1987-05-16
FI84076B (fi) 1991-06-28
PT82186B (pt) 1988-04-21
JP2562809B2 (ja) 1996-12-11
HU206381B (en) 1992-10-28
NZ215350A (en) 1989-03-29
ATE159954T1 (de) 1997-11-15
DK121486D0 (da) 1986-03-14
IE66673B1 (en) 1996-01-24
DE3650655T2 (de) 1998-03-12
PT82186A (en) 1986-04-01
DE3650655D1 (de) 1997-12-11
AU5476086A (en) 1986-10-16
GB8506792D0 (en) 1985-04-17
CA1300130C (en) 1992-05-05
EP0197571B1 (en) 1995-06-21

Similar Documents

Publication Publication Date Title
KR930007386B1 (ko) γ-사이클로덱스트린 유도체의 제조방법
US4870060A (en) Derivatives of γ-cylodextrin
FI86140B (fi) Foerfarande foer framstaellning av en farmaceutisk beredning som innehaoller ett i vatten svaorloesligt eller i vatten instabilt laekemedel.
US6407079B1 (en) Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4727064A (en) Pharmaceutical preparations containing cyclodextrin derivatives
EP2467379B1 (en) Process for the production of coevaporates and complexes comprising voriconazole and cyclodextrin
PL195280B1 (pl) Kompleks inhibitora RAS-farnezylotransferazy o ulepszonej rozpuszczalności w wodzie i trwałości oraz kompozycja inhibitora RAS-farnezylotransferazy
HU214338B (hu) Eljárás taxoltartalmú ciklodextrin zárványtermék előállítására
EP1272531B1 (en) Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
FI86507B (fi) Foerfarande foer framstaellning av terapeutiska kompositioner innehaollande y-cyklodextrinderivat.
US6984632B1 (en) Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
IE950700L (en) Novel derivatives of þ-cyclodextrin
KR920008700B1 (ko) 수-난용성 또는 수-불안정성 약제와 β-사이클로덱스트린 에테르의 수용성 복합체의 제조방법
KR20050105565A (ko) 저장안정성이 우수한 벤즈이미다졸 유도체 함유 포접복합체 및 이의 제조방법
KR20070069567A (ko) 저장안정성이 우수한 ｓ-오메프라졸 함유 포접 복합체 및이의 제조방법
NO171888B (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat inneholdende medisinske stoffer som er lite opploeselige eller ustabile i vann
CA2189863C (en) Mucoadhesive emulsions containing cyclodextrin
DK200201960A (da) Nye derivater af y-cyclodextrin, fremgangsmåder til deres fremstilling samt præparater indeholdende disse og fremgangsmåder til deres fremstilling

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19860206

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19910202

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19860206

Comment text: Patent Application

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19930715

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19931108

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19931222

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19931222

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19960809

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 19970805

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 19971230

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 19990729

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20000802

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20010801

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20020723

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20030723

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20040723

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20050722

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20050722

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term